A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

NCT01936688 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Plaque-type Psoriasis

Interventions

DRUG: MK-3222 200 mg
DRUG: MK-3222 100 mg
DRUG: Placebo to MK-3222
DRUG: Placebo to Etanercept
DRUG: Etanercept 50 mg

Sponsor

Sun Pharmaceutical Industries Limited